Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer.
Background: Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PDL-1) inhibitors have improved survival over chemotherapy in advanced Non- Small Cell Lung Cancer (NSCLC). However, it is unclear if there are class specific differences in the efficacy of Checkpoint Inhibitors (CPIs) in NSCLC, an...
| Publicado en: | Journal of Oncology Pharmacy Practice Vol. 27; pp. 405 - 414 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research systematic review tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
Mar2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148905758&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 148905758 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10781552 0JI jtl: Journal of Oncology Pharmacy Practice issn: 10781552 maglogo: Y pubinfo: dt: Mar2021 vid: 27 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 148905758 146728517 148905758 148905758 10.1177/1078155220964903 148905758 ppf: 405 ppct: 9 formats: tig: atl: Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer. aug: au: Bozcuk, Hakan Artaç, Mehmet Mutlu, Hasan Sever, Özlem Yıldırım, Mustafa affil: Department of Medical Oncology, Medical Park Hospital, Antalya, Turkey sug: subj: Carcinoma, Non-Small-Cell Lung Drug Therapy Programmed Cell Death Protein 1 Receptor Antagonists and Inhibitors Programmed Cell Death Ligand 1 Antagonists and Inhibitors Immune Checkpoint Inhibitors Therapeutic Use Carcinoma, Non-Small-Cell Lung Prognosis Treatment Outcomes Drug Efficacy Human Systematic Review Meta Analysis Survival Analysis PubMed Confidence Intervals Comparative Studies Antineoplastic Agents Pharmacodynamics ab: Background: Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PDL-1) inhibitors have improved survival over chemotherapy in advanced Non- Small Cell Lung Cancer (NSCLC). However, it is unclear if there are class specific differences in the efficacy of Checkpoint Inhibitors (CPIs) in NSCLC, and this paper is designed to answer these clinical questions. Methods: For this Meta-analysis, we searched PubMed, Science of Web, "Clinicaltrials.gov" and online sources for trials comparing PD-1 and PDL-1 CPIs in advanced NSCLC. The data for Hazard Ratio (HR) and their Confidence Intervals (CI) for Overall Survival (OS) was extracted. Results: A sum of 9739 patients from 16 trials were included in the efficacy evaluation. For the OS endpoint, both PD-1 inhibitors (HR = 0.76, 95%CI = 0.69–0.83, P < 0.001) and PDL-1 inhibitors (HR = 0.84, 95%CI = 0.74–0.95, P < 0.001) were superior to chemotherapy in treatment naïve (upfront) patients, the results were similar in treatment refractory patients (PD-1 inhibitors (HR = 0.67, 95%CI = 0.60–0.75, P < 0.001) and PDL-1 inhibitors (HR = 0.78, 95%CI = 0.69–0.88, P < 0.001) were superior to chemotherapy). There was no difference in the effect of PD-1 and PDL-1 classes of CPIs over chemotherapy in treatment naïve and treatment refractory settings (Q = 1.88, df = 1, P = 0.017, and, Q = 3.27, df = 1, P = 0.070, respectively). Conclusion: Efficacy of PD-1 and PDL-1 class of CPIs was not different, although differences among individual CPIs or their combinations cannot be excluded. We were also able to compute pooled efficacy data, as compared to chemotherapy alone, for trials where these groups of CPIs were utilized. pubtype: Academic Journal doctype: meta analysis research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|